OrganovoONVO
ONVO
$0.5070
2.5%
Market Cap: $7.79M
About: Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Employees: 20
0
Funds holding %
of 6,710 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
86% more capital invested
Capital invested by funds: $955K [Q1] → $1.77M (+$818K) [Q2]
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
6.96% more ownership
Funds ownership: 9.23% [Q1] → 16.19% (+6.96%) [Q2]
0% more funds holding
Funds holding: 34 [Q1] → 34 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for ONVO.